-
ESMO Exclusive Interview | Professor Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place in Madrid, Spain, from October 20th to 24th. The Oncology Frontier team delved into the frontline, capturing international advancements and witnessing the strides made by China in the global oncology arena. Professor Changsong Qi from Peking University Cancer Hospital delivered a crucial oral…
-
ESMO 2023丨Professor Zhimin Shao: monarcE Study 5-Year Follow-Up Data Revealed, Sustained Benefit for Patients
The monarchE study is a randomized, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of abemaciclib combined with endocrine therapy versus endocrine therapy alone in HR+, HER2-high-risk early-stage breast cancer patients. Since the disclosure of relevant data in March 2020, the study results have been updated multiple times, establishing the…
-
ESMO Hot Topic | Professor Xinan Sheng: HIF-2α Inhibitor Offers New Targeted Treatment Option for Advanced Renal Clear Cell Carcinoma Patients
The treatment of advanced renal clear cell carcinoma (ccRCC) has evolved from the cytokine era to the era of targeted therapy, immunotherapy, and immunotherapy combinations, expanding survival options for patients. However, results from the CONTACT-03 study suggest that continuing with immunotherapy combinations after immunotherapy failure may not be a preferred option, highlighting the need for…
-
ESMO Highlights | Professor WeiYu’s Commentary on Advances in Neoadjuvant Therapy and Bladder Preservation in Bladder Cancer
Bladder cancer is a common tumor in the urinary system, with muscle-invasive bladder cancer (MIBC) accounting for approximately 20% of all bladder cancers. Nearly half of non-muscle-invasive bladder cancer (NMIBC) patients may relapse into MIBC. Currently, various explorations in neoadjuvant therapy, including chemotherapy, immunotherapy, and their combination, have been conducted. The recent ESMO conference revealed…
-
ESMO 2023 | Professor Zhongsheng Tong: New Trop-2 ADC Brings New Hope for HR+/HER2- Advanced Breast Cancer Patients
According to the cancer burden data released by the World Health Organization, hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 60%. The treatment strategies and survival benefits for first-line and subsequent-line therapy for HR+/HER2- advanced breast cancer have been a hot topic. The TROPION-Breast01 study data, unveiling…
-
ESMO China Voice | Professor Xiaohua Wu’s Team Presents Two LBA Studies at ESMO, Adding Chinese Solutions to Gynecological Cancer Treatment
On October 20, the 2023 European Society for Medical Oncology (ESMO) Congress officially opened in Madrid, Spain. As one of the most influential global oncology conferences, top experts from around the world gathered to discuss and share the latest international research findings and cancer treatment technologies. Professor Xiaohua Wu’s team from Fudan University Affiliated Cancer…
-
ESMO 2023: EGFR-MET Dual-Specific Antibody Combination Emerges as a New Option for EGFR-Mutant Advanced NSCLC
According to the reports from Phase III MARIPOSA and MARIPOSA-2 trials presented at the 2023 ESMO Presidential Symposium, Amivantamab combination therapy demonstrated clinically significant improvements in both first-line and second-line treatments compared to standard therapy (Abstract Numbers LBA14 and LBA15).
-
ESMO in Five Minutes | Prof. Haitao Zhao : Highlights of Advances in the Treatment of Cholangiocarcinoma
Fibroblast Growth Factor Receptor inhibitors (FGFRi) have been shown to play a role in the treatment of cholangiocarcinoma (CCA) with FGFR alterations after chemotherapy. However, disease progression occurs after 6-8 months. Secondary multiclonal mutations in the FGFR2 kinase domain represent a notable acquired resistance mechanism. Tinengotinib is identified as a novel FGFRi with high efficacy…
Connecting Medical Expertise through Media